• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Bimekizumab superior to secukinumab for plaque psoriasis treatment

byCamille ZeitouniandHarsh Shah
May 3, 2021
in Chronic Disease, Dermatology, Rheumatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Bimekizumab treatment was shown to be noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab treatment.

2. Bimekizumab treatment was shown to have a higher risk for oral candidiasis infection compared to secukinumab treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The pathology of psoriasis involves the overexpression of interleukin-17A and interleukin-17F in tissue lesions. In this randomized controlled trial, the biologic secukinumab, a selective inhibitor of interleukin-17A was compared to bimekizumab, an inhibitor of both interleukin-17A and interleukin-17F, for the treatment of plaque psoriasis. The study determined bimekizumab was both noninferior and superior to secukinumab for complete skin clearance of psoriatic lesions using the Psoriasis Area and Severity Index (PASI) score. Both trial groups experienced similar adverse events, however, the incidence of oral candidiasis was greater in the patients receiving bimekizumab treatment. This study provided strong justification for bimekizumab use compared to secukinumab in patients with plaque psoriasis. The major limitation of this study was its exclusion of patients who had previously failed to respond to an anti-interleukin-17 biologic agent, thereby limiting the generalizability of these findings to all psoriasis patients. Nonetheless, the findings were significant, as more patients achieved full skin clearance on bimekizumab compared to secukinumab.

Click to read the study in NEJM

Relevant Reading: Bimekizumab versus Adalimumab in Plaque Psoriasis

In-Depth [randomized controlled trial]: This multicenter, double-blind, randomized controlled trial enrolled 743 patients between June 13, 2018, and May 8, 2019. Patients aged 18 or older with moderate-to-severe plaque psoriasis which was diagnosed at least six months prior to screening were eligible for participation in the trial. Patients who had previously taken bimekizumab or secukinumab or showed no response to an anti-interleukin-17 biologic agent were excluded from the trial. Patients with a PASI score of 12 or more – score ranges from 0-72, with severity increasing with higher scores – were deemed to have moderate-to-severe psoriasis, and the scoring system was used to measure the effectiveness of treatment. Patients were randomized in a 1:1 ratio to receive either bimekizumab or secukinumab for 16 weeks, respectively. The primary endpoint was the rate of complete skin clearance defined as a 100% reduction of PASI score from baseline. After 16 weeks, 181 (48.9%) patients receiving secukinumab compared to 230 (61.7%) patients receiving bimekizumab had complete skin clearance (adjusted risk difference, 12.7 percentage points; 95% confidence interval [CI], 5.8 to19.6, P < 0.001). At the 16-week time point, patients receiving bimekizumab were further randomized in a 2:1 ratio to receive maintenance therapy every eight weeks or every four weeks, respectively. At 48 weeks, bimekizumab was still shown to be superior after maintenance in patients receiving bimekizumab every four weeks or every eight weeks compared to secukinumab every four weeks. While the incidences of adverse events, serious adverse events, and adverse events leading to discontinuation were similar in patients receiving either medication, oral candidiasis infections occurred in 72 patients (19.3%) receiving bimekizumab compared to 11 patients (3.0%) receiving secukinumab. Overall, bimekizumab treatment was shown to noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab treatment; however, bimekizumab treatment was shown to have an increased risk of developing oral candidiasis infections.

RELATED REPORTS

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

#VisualAbstract: Sonelokimab showed significant clinical benefit over placebo in patients with plaque psoriasis

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bimekizumabplaque psoriasisSecukinumab
Previous Post

Sepsis performance measure implementation not associated with clinical outcomes improvement

Next Post

Ambulatory blood pressure monitoring remains the reference standard for hypertension screening over office-based measurement: US Preventive Services Task Force

RelatedReports

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis
StudyGraphics

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

April 7, 2022
#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa
StudyGraphics

#VisualAbstract Drug survival of etanercept was significantly lower than other biologics in patients with hidradenitis suppurativa

December 23, 2021
#VisualAbstract: Sonelokimab showed significant clinical benefit over placebo in patients with plaque psoriasis
StudyGraphics

#VisualAbstract: Sonelokimab showed significant clinical benefit over placebo in patients with plaque psoriasis

May 12, 2021
Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)
Chronic Disease

Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis

May 5, 2021
Next Post
UTI associated with increased risk of preeclampsia

Ambulatory blood pressure monitoring remains the reference standard for hypertension screening over office-based measurement: US Preventive Services Task Force

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

Combined MRI and NIH stroke scores may predict stroke prognosis

Intracerebral hemorrhage may be an independent risk factor for arterial ischemic events

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.